Welcome, Guest. Please login or register.
July 18, 2024, 04:22:54 pm

Login with username, password and session length


Members
Stats
  • Total Posts: 55130
  • Total Topics: 4851
  • Online Today: 203
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 87
Total: 87

Welcome

Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Updated data re hepatocellular carcinoma recurrence post DAA  (Read 10166 times)

0 Members and 1 Guest are viewing this topic.

Offline lporterrn

  • Member
  • Posts: 1,969
  • LucindaPorterRN
    • LucindaPorterRN
For those of you who heard the EASL data regarding hepatocellular carcinoma recurrence post DAA treatment, this suggests we don't have enough evidence to make the connection:
http://www.natap.org/2016/HCV/061716_01.htm][url]http://www.natap.org/2016/HCV/061716_01.htm[/url]
Lucinda Porter, RN
1988 Contracted HCV
1997 Interferon nonresponder
2003 PEG + ribavirin responder-relapser
2013 Cured (Harvoni + ribavirin clinical trial)
https://www.hepmag.com/blogger/lucindakporter

Offline Philadelphia

  • Global Moderator
  • Member
  • Posts: 1,157
  • It only looks like I know what I'm doing
Re: Updated data re hepatocellular carcinoma recurrence post DAA
« Reply #1 on: July 15, 2016, 08:34:41 am »
Interesting! The link is a little funky - any chance you can edit it?
CURED SVR24  Class of 2015
Wk 12 post EOT 30.11.15: ALT 14 AST 22 GGT 22 VL UND
Week 19 07.08.15: ALT 17 AST 23 GGT 25
Week 12 18.06.15: ALT 21 AST 23 GGT 28
Week 8 25.05.15: ALT 23 AST 27 GGT 30 VL UND
Week 4 20.04.14: ALT 30 AST 36 VL 40
Treatment start 23.03.15: ALT 137 AST 185 VL 342,600
Cirrhosis Child-Pugh A, Genotype 1a - Viekira Pak + riba 24 weeks
Total failure interferon/ribavirin/boceprovir Mar 2013
https://www.hepmag.com/blogger/grace-campbell

Offline KimInTheForest

  • Member
  • Posts: 1,972
  • Believe in yourself
Re: Updated data re hepatocellular carcinoma recurrence post DAA
« Reply #2 on: July 15, 2016, 02:26:50 pm »
Here is an unfunkied version of the link:

http://www.natap.org/2016/HCV/061716_01.htm
Kim Goldberg (Nanaimo, BC)
1970s: Contracted HCV (genotype 3a)
2015: Cured with Harvoni + ribavirin (12 weeks)
MY STORY: https://pigsquash.wordpress.com/2016/01/28/undetectable-my-hep-c-story/

Offline Philadelphia

  • Global Moderator
  • Member
  • Posts: 1,157
  • It only looks like I know what I'm doing
Re: Updated data re hepatocellular carcinoma recurrence post DAA
« Reply #3 on: July 15, 2016, 05:53:00 pm »
I mean ... I like funk, I'm all for funk. But I prefer it in my music not my links. Thanks Kim. :)
CURED SVR24  Class of 2015
Wk 12 post EOT 30.11.15: ALT 14 AST 22 GGT 22 VL UND
Week 19 07.08.15: ALT 17 AST 23 GGT 25
Week 12 18.06.15: ALT 21 AST 23 GGT 28
Week 8 25.05.15: ALT 23 AST 27 GGT 30 VL UND
Week 4 20.04.14: ALT 30 AST 36 VL 40
Treatment start 23.03.15: ALT 137 AST 185 VL 342,600
Cirrhosis Child-Pugh A, Genotype 1a - Viekira Pak + riba 24 weeks
Total failure interferon/ribavirin/boceprovir Mar 2013
https://www.hepmag.com/blogger/grace-campbell

Offline lporterrn

  • Member
  • Posts: 1,969
  • LucindaPorterRN
    • LucindaPorterRN
Re: Updated data re hepatocellular carcinoma recurrence post DAA
« Reply #4 on: July 15, 2016, 08:14:59 pm »
Thanks Kim - I am on vacation and losing my media skills.  :P
Lucinda Porter, RN
1988 Contracted HCV
1997 Interferon nonresponder
2003 PEG + ribavirin responder-relapser
2013 Cured (Harvoni + ribavirin clinical trial)
https://www.hepmag.com/blogger/lucindakporter

Offline Lynn K

  • Global Moderator
  • Member
  • Posts: 4,545
  • Get tested, get treated, get cured, fight Hep c!
Re: Updated data re hepatocellular carcinoma recurrence post DAA
« Reply #5 on: July 27, 2016, 01:56:12 am »
FUNKY  8)
Genotype 1a
1978 contracted, 1990 Dx
1995 Intron A failed
2001 Interferon Riba null response
2003 Pegintron Riba trial med null response
2008 F4 Cirrhosis Bx
2014 12 week Sov/Oly relapse
10/14 fibroscan 27 PLT 96
2014 24 weeks Harvoni 15 weeks Riba
5/4/15 EOT not detected, ALT 21, AST 20
4 week post not detected, ALT 26, AST 28
12 week post NOT DETECTED (07/27/15)
ALT 29, AST 27 PLT 92
24 week post NOT DETECTED! (10/19/15)
44 weeks (3/11/16)  fibroscan 33, PLT 111, HCV NOT DETECTED!
I AM FREE!

Offline Mike716

  • Member
  • Posts: 15
  • Here's looking at you. . .
Re: Updated data re hepatocellular carcinoma recurrence post DAA
« Reply #6 on: July 29, 2016, 11:01:22 pm »
For those of you who heard the EASL data regarding hepatocellular carcinoma recurrence post DAA treatment, this suggests we don't have enough evidence to make the connection:
[url]http://www.natap.org/2016/HCV/061716_01.htm]http://www.natap.org/2016/HCV/061716_01.htm][url]http://www.natap.org/2016/HCV/061716_01.htm[/url]

I take exception, lporterrn, with your statement above regarding these studies, that "we don't have enough evidence to make the connection" between DAAs and recurring HCC. It suggests that there is a connection but that we simply haven't enough evidence yet to prove it. I read the French paper and, on the contrary, the French study presents plenty of evidence, more and more convincing than the study presented at EASL or the others with similar conclusions, that it is simply untrue.

In support of its contrary conclusion (that DAA treatment does not increase the risk of recurrence of HCC), the French study states: "The prospective follow-up of a large number of patients included in three distinct cohorts of patients reflecting various clinical profiles ensures the quality of our analyses and the confidence in our conclusions."

The heading of the NATAP webpage cited above - "Lack of evidence...(etc.)" - is misleading. Not finding evidence that supports a certain conclusion, after a broad and in-depth study searching for such evidence, is not the same thing as "lack of evidence" or "we don't have enough evidence".

In scientific matters it pays to be careful with language. Catch-phrases like "lack of evidence" can easily be misused. Scientific studies are often done to disprove a certain hypothesis by looking for evidence of it and, finding none, concluding it thereby disproved. This in no way suggests that there was any "lack of evidence" in the study. A double negative is positive. If evidence means anything, a thorough study finding no evidence to show that x is negative is a partial proof, at the very least, that x is not negative. To say that there was no evidence to support such a conclusion is absurd.

After reading the French study, I believe we can safely say that the information presented at EASL was based on an insufficient and inaccurate study, and that, so far as we know, treatment with DAAs does not increase the risk of a recurrence of HCC.
Diag. 2008: HCV geno 1a
Biopsy 2008: F1-F2
Fibroscan 2012: F2-F3
Fibrotest 2015: F4 (& AST 150)
Tx 2015: Sovaldi+Olysio, 12 wks.
EOT+3mos. VL: UND
EOT+15 mos. VL: UND

Offline Mike716

  • Member
  • Posts: 15
  • Here's looking at you. . .
Re: Updated data re hepatocellular carcinoma recurrence post DAA
« Reply #7 on: July 29, 2016, 11:28:15 pm »
I neglected to mention that I found the French paper's discussion of possible errors in procedure leading to mistaken conclusions in previous studies highly interesting. It is worth a read, for anyone concerned with this rather serious subject.
Diag. 2008: HCV geno 1a
Biopsy 2008: F1-F2
Fibroscan 2012: F2-F3
Fibrotest 2015: F4 (& AST 150)
Tx 2015: Sovaldi+Olysio, 12 wks.
EOT+3mos. VL: UND
EOT+15 mos. VL: UND

Offline Philadelphia

  • Global Moderator
  • Member
  • Posts: 1,157
  • It only looks like I know what I'm doing
Re: Updated data re hepatocellular carcinoma recurrence post DAA
« Reply #8 on: July 30, 2016, 03:32:05 am »
I interpreted what Lucinda said very differently to you. My take on her words was that she was saying was that the quoted French study was showing the original study by Buonfiglioli did not have enough evidence. If that makes sense ...
CURED SVR24  Class of 2015
Wk 12 post EOT 30.11.15: ALT 14 AST 22 GGT 22 VL UND
Week 19 07.08.15: ALT 17 AST 23 GGT 25
Week 12 18.06.15: ALT 21 AST 23 GGT 28
Week 8 25.05.15: ALT 23 AST 27 GGT 30 VL UND
Week 4 20.04.14: ALT 30 AST 36 VL 40
Treatment start 23.03.15: ALT 137 AST 185 VL 342,600
Cirrhosis Child-Pugh A, Genotype 1a - Viekira Pak + riba 24 weeks
Total failure interferon/ribavirin/boceprovir Mar 2013
https://www.hepmag.com/blogger/grace-campbell

Offline Mike716

  • Member
  • Posts: 15
  • Here's looking at you. . .
Re: Updated data re hepatocellular carcinoma recurrence post DAA
« Reply #9 on: July 30, 2016, 04:03:16 am »
Quote
If that makes sense ...

Yeah, well, it sorta makes sense, Philly. :-)

The point I was trying to make is that they all present evidence, it's just that not all of them present valid evidence. The French study was done very well and its conclusions are justified. The others weren't done well and their conclusions aren't justified.

If you read the French paper I think you will find their discussion of the faults of the previous studies particularly interesting. For example, the study presented at EASL included patients who had received non-curative HCC treatments, that is, patients who had HCC after Tx with DAAs not because the DAAs promoted HCC but because they were never cured of their pre-existing HCC.

In any case, there's plenty of evidence floating around, it's just that some of it is tosh. If you get my point.

M.
Diag. 2008: HCV geno 1a
Biopsy 2008: F1-F2
Fibroscan 2012: F2-F3
Fibrotest 2015: F4 (& AST 150)
Tx 2015: Sovaldi+Olysio, 12 wks.
EOT+3mos. VL: UND
EOT+15 mos. VL: UND

Offline Mugwump

  • Member
  • Posts: 778
  • My number of posts means nothing, piscor ergo sum!
Re: Updated data re hepatocellular carcinoma recurrence post DAA
« Reply #10 on: August 28, 2016, 06:32:27 pm »
What would be more informative is a study of how the level of liver damage in general increases the risks of HCC. If there is a comparison of rates of HCV infected individuals who have less liver damage and then go on after cure to develop HCC in comparison to those who have greater liver damage.

Either way some of the data seems to indicate that some people lose their ability to effectively fight off HCC post treatment and this is a huge concern. It is looking more and more like curing HCV does effect the human immune system in ways that we do not completely understand.

My suspicion is that the levels of natural cancer fighting interferon are effected by a sudden proportional increase in healthy liver cells. And those who have cells that are already becoming pre cancerous then do not have as great an ability to clear the troubled cells.

It is ironic that it is the death of liver cells that triggers interferon production and is a natural mechanism to fight off whatever agents are causing the liver cells to die. Essentially, to some extent, it was the death of liver cells that helped keep HCV in check, just perhaps it also kept HCC in check as well.

There is so much to learn about liver chemistry and we are just starting to understand the extremely complex interdependent nature of how the organ works.   
Caution shameless self promotion below :-)
https://www.hepmag.com/article/eric-reesor-27742-782589663
DING DONG MY DRAGON (HCV) IS FINALLY DEAD!

 


© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.